The extract below ( full articles are always available ) from research concerning Chinese Medicine shows positive results in expiratory volume and flow values.
“Anti-IgE therapy is beneficial for some asthmatics, however its effects are transient and cysteinyl leukotriene inhibitors have shown only limited efficacy(11,12). Recently, safety concerns regarding both of these therapies have been raised(13,14). Thus, a safe, effective and long-lasting therapy remains to be established.
In recent years, a small, but increasing number of well-controlled clinical trials of some CM Anti-Asthma Simplified Herbal Medicine Intervention (ASHMI)(16), Dingchuan Decoction (定喘汤, DCD)(17), STA-1(18), provide some evidence of clinical efficacy, including immunomodulatory effects(16,18). There are also increases in laboratory studies focusing on actions and mechanisms of actions of anti-asthma herbal medicines using in vitro and in vivo models. This paper reviews English language publications on CM herbal medicines for asthma, evidence- based research into their efficacy and mechanisms underlying efficacy published between 2006 and 2011.
ASHMI, developed by Dr. Li and colleagues is an investigational new drug approved by U.S. Food and Drug Administration for asthma (ASHMI is composed of 3 herbs, Table 1). Previously Wen, et al(16) reported the first double-blind, randomized, placebo-controlled trial (RCT) investigating the efficacy and tolerability of ASHMI compared with oral prednisone therapy in 91 patients with moderate-to- severe asthma. Treatment was administered daily over 4 weeks. This study found that post treatment, lung function
significantly improved in both groups, and clinical symptom scores, use of β2-bronchodilators and serum IgE levels and Th2 cytokine levels were reduced in both groups. However, in contrast to prednisone, ASHMI significantly increased serum interferon-γ (IFN-γ) and cortisol levels. No significant side effects were observed. Kelly- Piper, et al(19) conducted a double blind, placebo controlled, dose escalation safety trial (phase I) in 18 adult asthma individuals and showed that ASHMI is safe and well tolerated.”
Chin J Integr Med 2011 Jul;17(7):483-491